Codexis (CDXS) versus Galectin Therapeutics (GALT) Critical Survey
Codexis (NASDAQ: CDXS) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap industrial products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.
Risk & Volatility
Codexis has a beta of -1.59, indicating that its share price is 259% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 2.56, indicating that its share price is 156% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Codexis and Galectin Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Codexis presently has a consensus target price of $7.81, indicating a potential upside of 12.82%. Galectin Therapeutics has a consensus target price of $5.25, indicating a potential upside of 116.05%. Given Galectin Therapeutics’ higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Codexis.
This table compares Codexis and Galectin Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Codexis and Galectin Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Codexis||$48.84 million||6.86||-$8.55 million||($0.65)||-10.65|
|Galectin Therapeutics||N/A||N/A||-$21.43 million||($0.55)||-4.42|
Codexis has higher revenue and earnings than Galectin Therapeutics. Codexis is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
65.7% of Codexis shares are owned by institutional investors. Comparatively, 11.1% of Galectin Therapeutics shares are owned by institutional investors. 9.8% of Codexis shares are owned by company insiders. Comparatively, 38.8% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Receive News & Stock Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related stocks with our FREE daily email newsletter.